

## MGC Pharma awarded three-year GMP licence for EU cannabinoid medicine production facility

A  
S  
X  
  
R  
E  
L  
E  
A  
S  
E

### Key Highlights:

- MGC Pharma’s Slovenian production and compounding facility awarded three-year GMP licence from EU authorities, required for the production of pharma grade cannabinoid-based medicines (IMP) and products
- A landmark achievement for MXC with the GMP licence renewed for 3 years
- Renewal following completion of regulatory audit, demonstrating high quality internal processes and compliance with strict EU standards
- 3-year GMP licence delivers material certainty for MXC’s production capacity for delivery on future revenue streams, commercial development, IP and EU manufacturing asset value
- Reinforces MXC’s ability to deliver on its target production of 5,000 units per month by the start of calendar year 2021 from existing supply and distribution agreements in place

**MGC Pharmaceuticals Ltd (ASX: MXC, ‘MGC Pharma’ or ‘the Company’)**, a European based bio-pharma company specialising in the production and development of phytocannabinoid-derived medicines, is pleased to announce an annual audit conducted by the JAZMP, the government agency of medicinal products and medical devices of the Republic of Slovenia, has completed its facility audit and has successfully renewed MXC’s Good Manufacturing Practice (“**GMP**”) licence for EU compliance of its Slovenian production and compounding facility, for a further three (3) years.

The EU GMP licence is the most highly credentialled in the world for compliance and is essential for the production and manufacturing of pharma grade medicinal products. This represents a landmark achievement for the Company as receipt of a licence for three years, confirming compliance with strict European quality standards for production and manufacturing of pharmaceutical grade products.

The award of this licence also delivers material certainty on MXC’s capacity to produce EU GMP cannabinoid-based Investigational Medicinal Products (“**IMP**”) including CannEpi<sup>®</sup> and CogniCann<sup>®</sup> from its facility, future commercial development, intellectual property (IP) and unique EU manufacturing asset valuation.

As a result, MGC Pharma can continue to research, develop, produce and manufacture its suite of proprietary CBD and THC products from its Slovenian EU GMP production facility. This 3-year renewal reinforces the Company’s ability to deliver on its target production of 5,000 units per month from the Slovenian facility by the start of calendar year 2021 from existing supply and distribution agreements currently in place.

**Roby Zomer, Co-founder and Managing Director of MGC Pharma, commented:** “Authorities usually issue GMP licences with a one-year term so receiving a three-year GMP licence is a great achievement and a real testament to the quality of our products, staff and the facility.”

--Ends--

**Authorised for release by the Board, for further information please contact:**

**PR/IR Advisors – Media & Capital Partners**

Melissa Hamilton (PR) +61 417 750 274

Rod Hinchcliffe (IR) +61 412 277 377

[Melissa.hamilton@mcpartners.com.au](mailto:Melissa.hamilton@mcpartners.com.au)

[Rod.Hinchcliffe@mcpartners.com.au](mailto:Rod.Hinchcliffe@mcpartners.com.au)

**MGC Pharmaceuticals Ltd**

Brett Mitchell

Executive Chairman

+61 8 6382 3390

[info@mgcpharma.com.au](mailto:info@mgcpharma.com.au)

## About MGC Pharma

MGC Pharmaceuticals Ltd (ASX: MXC) is a European based bio-pharma company developing and supplying affordable standardised phytocannabinoid derived medicines to patients globally. The Company's founders were key figures in the global medical cannabis industry and the core business strategy is to develop and supply high quality phytocannabinoid derived medicines for the growing demand in the medical markets in Europe, North America and Australasia. MGC Pharma has a robust product offering targeting two widespread medical conditions – epilepsy and dementia – and has further products in the development pipeline.

Employing its 'Nature to Medicine' strategy, MGC Pharma has partnered with renowned institutions and academia to optimise cultivation and the development of targeted phytocannabinoid derived medicines products prior to production in the Company's EU-GMP Certified manufacturing facility. MGC Pharma has a number of research collaborations with world renowned academic institutions, and including recent research highlighting the positive impact of using specific phytocannabinoid formulations developed by MGC Pharma in the treatment of glioblastoma, the most aggressive and so far therapeutically resistant primary brain tumour.

MGC Pharma has a growing patient base in Australia, the UK, Brazil and Ireland and has a global distribution footprint via an extensive network of commercial partners meaning that it is poised to supply the global market.

Follow us through our social media channels

